Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-06-04
2001-10-23
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
06306820
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the field of TNF-mediated diseases. More specifically, the present invention relates to combination therapy for the purpose of preventing or treating TNF-mediated diseases.
BACKGROUND OF THE INVENTION
Inflammation is the body's defense reaction to injuries such as those caused by mechanical damage, infection or antigenic stimulation. An inflammatory reaction may be expressed pathologically when inflammation is induced by an inappropriate stimulus such as an autoantigen, is expressed in an exaggerated manner or persists well after the removal of the injurious agents. Such inflammatory reaction may include the production of certain cytokines.
While the etiology of inflammation is poorly understood, considerable information has recently been gained regarding the molecular aspects of inflammation. This research has led to identification of certain cytokines which are believed to figure prominently in the mediation of inflammation. Cytokines are extracellular proteins that modify the behavior of cells, particularly those cells that are in the immediate area of cytokine synthesis and release. Tumor necrosis factors (TNFs) are a class of cytokines produced by numerous cell types, including monocytes and macrophages.
At least two TNFs have been previously described, specifically TNF alpha (TNF-&agr;) and TNF beta (TNF-&bgr; or lymphotoxin), and each is active as a trimeric molecule and is believed to initiate cellular signaling by crosslinking receptors (Engelmann et al. (1990),
J. Biol. Chem.,
265:14497-14504).
Several lines of evidence implicate TNF-&agr; and TNF-&bgr; as major inflammatory cytokines. These known TNFs have important physiological effects on a number of different target cells which are involved in inflammatory responses to a variety of stimuli such as infection and injury. The proteins cause both fibroblasts and synovial cells to secrete latent collagenase and prostaglandin E
2
and cause osteocyte cells to stimulate bone resorption. These proteins increase the surface adhesive properties of endothelial cells for neutrophils. They also cause endothelial cells to secrete coagulant activity and reduce their ability to lyse clots. In addition they redirect the activity of adipocytes away from the storage of lipids by inhibiting expression of the enzyme lipoprotein lipase. TNFs also cause hepatocytes to synthesize a class of proteins known as “acute phase reactants,” which act on the hypothalamus as pyrogens (Selby et al. (1988),
Lancet,
1 (8583):483; Starnes, Jr. et al. (1988),
J. Clin. Invest.,
82:1321; Oliff et al. (1987),
Cell,
50:555; and Waage et al. (1987),
Lancet,
1 (8529):355).
A disease or medical condition is considered to be a “TNF-mediated disease” if the spontaneous or experimental disease is associated with elevated levels of TNF in bodily fluids or in tissues adjacent to the focus of the disease or indication within the body. TNF-mediated diseases may also be recognized by the following two conditions: (1) pathological findings associated with a disease can be mimicked experimentally in animals by the administration of TNF and (2) the pathology induced in experimental animal models of the disease can be inhibited or abolished by treatment with agents which inhibit the action of TNF. Many TNF-mediated diseases satisfy two of these three conditions, and others will satisfy all three conditions.
TNF-mediated diseases such as rheumatoid arthritis and psoriatic arthritis are chronic joint diseases that afflict and disable, to varying degrees, millions of people worldwide. Rheumatoid arthritis is a disease of articular joints in which the cartilage and bone are slowly eroded away by a proliferative, invasive connective tissue called pannus, which is derived from the synovial membrane. The disease may involve peri-articular structures such as bursae, tendon sheaths and tendons as well as extra-articular tissues such as the subcutis, cardiovascular system, lungs, spleen, lymph nodes, skeletal muscles, nervous system (central and peripheral) and eyes (Silberberg (1985),
Anderson's Pathology,
Kissane (ed.), II:1828).
It is believed that rheumatoid arthritis results from the presentation of a relevant antigen to an immunogenetically susceptible host. The antigens that could potentially initiate an immune response resulting in rheumatoid arthritis might be endogenous or exogenous. Possible endogenous antigens include collagen, mucopolysaccharides and rheumatoid factors. Exogenous antigens include mycoplasms, mycobacteria, spirochetes and viruses. By-products of the immune reaction inflame the synovium (i.e., prostaglandins and oxygen radicals) and trigger destructive joint changes (i.e., collagenase).
There is a wide spectrum of disease severity, but many patients run a course of intermittent relapses and remissions with an overall pattern of slowly progressive joint destruction and deformity. The clinical manifestations may include symmetrical polyarthritis of peripheral joints with-pain, tenderness, swelling and loss of function of affected joints; morning stiffness; and loss of cartilage, erosion of bone matter and subluxation of joints after persistent inflammation. Extra-articular manifestations include rheumatoid nodules, rheumatoid vasculitis, pleuropulmonary inflammations, scleritis, sicca syndrome, Felty's syndrome (splenomegaly and neutropenia), osteoporosis and weight loss (Katz (1985),
Am. J. Med.,
79:24 and Krane and Simon (1986),
Advances in Rheumatology,
Synderman (ed.), 70(2):263-284). The clinical manifestations result in a high degree of morbidity resulting in disturbed daily life of the patient.
Additionally, preclinical results with various predictive animal models of rheumatoid arthritis have suggested that inhibition of TNF-&agr; can have a major impact on disease progression and severity (Dayer et al. (1994),
European Cytokine Network,
5(6):563-571 and Feldmann et al. (1995),
Annals Of The New York Academy Of Sciences,
66:272-278). Moreover, recent human clinical trials in rheumatoid arthritis with inhibitors of TNF have shown promising results (Rankin et al. (1995),
British Journal Of Rheumatology,
3(4):4334-4342; Elliott et al. (1995),
Lancet,
344:1105-1110; Tak et al. (1996),
Arthritis and Rheumatism,
39:1077-1081; Paleolog et al. (1996),
Arthritis and Rheumatism,
39:1082-1091 and Moreland et al. (1997),
New England Journal of Medicine,
337:141-147.).
It is an object of the present invention to provide therapeutic methods and compositions for the treatment of TNF-mediated diseases. This and other objects of the present invention will become apparent from the description hereinafter.
SUMMARY OF THE INVENTION
The present invention relates to therapies for preventing and treating TNF-mediated diseases in a patient. The present invention specifically relates to combination therapy using a TNF binding protein for preventing and treating TNF-mediated diseases, including rheumatic diseases, and the systemic inflammation and body weight loss associated therewith. The type of treatment herein referred to is intended for mammals, including humans.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4289690 (1981-09-01), Pestka et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5136021 (1992-08-01), Dembinski et al.
patent: 5153265 (1992-10-01), Shadle et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5211945 (1993-05-01), Wallach et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5359037 (1994-10-01), Wallach et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5446090 (1995-08-01), Harris
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5512544 (1996-04-01), Wallach et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5610279 (1997-03-01), Brockhaus et
Bendele Alison M.
Edwards III Carl K.
Sennello Regina M.
Amgen Inc.
Levy Ron K.
O'Hara Eileen B.
Odre Steven M.
Spector Lorraine
LandOfFree
Combination therapy using a TNF binding protein for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy using a TNF binding protein for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using a TNF binding protein for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2558406